PharmaSGP Holding SE / DE000A2P4LJ5
05.11.2024 - 10:02:28PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer
| EQS-Ad-hoc: PharmaSGP Holding SE / Key word(s): Personnel 05-Nov-2024 / 10:02 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Gräfelfing, November 05, 2024 – Peter Gerckens, who has been a member of the Management Board of PharmaSGP Holding SE as Chief Commercial Officer (CCO) since July 1, 2024, will take over the position of Chief Executive Officer (CEO) of the company on January 1, 2025. This was decided by the Supervisory Board today. Peter Gerckens succeeds Natalie Weigand in this position. She informed the Supervisory Board today that she has decided not to extend her contract, which expires at the end of the year. However, Natalie Weigand will remain associated with the company in an advisory role after her departure. * * * Contact PharmaSGP Holding SE Claudius Krause | Jakob Hafer (cometis AG) Lochhamer Schlag 1 82166 Gräfelfing | Germany Phone: +49 611 205855-0 E-Mail: ir@pharmasgp.com End of Inside Information 05-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | PharmaSGP Holding SE |
| Lochhamer Schlag 1 | |
| 82166 Gräfelfing | |
| Germany | |
| E-mail: | ir@pharmasgp.com |
| Internet: | https://pharmasgp.com |
| ISIN: | DE000A2P4LJ5 |
| WKN: | A2P4LJ |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Tradegate Exchange |
| EQS News ID: | 2022283 |
| End of Announcement | EQS News Service |
| |
2022283 05-Nov-2024 CET/CEST
